Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
| dc.rights.license | open | en_US |
| dc.contributor.author | LACOMBE, Karine | |
| dc.contributor.author | MOH, Raoul | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| hal.structure.identifier | Global Health in the Global South [GHiGS] | |
| dc.contributor.author | CHAZALLON, Corine | |
| dc.contributor.author | LEMOINE, Maud | |
| dc.contributor.author | SYLLA, Babacar | |
| dc.contributor.author | FADIGA, Fatoumata | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| hal.structure.identifier | Global Health in the Global South [GHiGS] | |
| dc.contributor.author | LE CARROU, Jerôme | |
| dc.contributor.author | MARCELLIN, Fabienne | |
| dc.contributor.author | KOUANFACK, Charles | |
| dc.contributor.author | CIAFFI, Laura | |
| dc.contributor.author | SARTRE, Michelle Tagni | |
| dc.contributor.author | SIDA, Magloire Biwole | |
| dc.contributor.author | DIALLO, Alpha | |
| dc.contributor.author | GOZLAN, Joel | |
| dc.contributor.author | SEYDI, Moussa | |
| dc.contributor.author | CISSÉ, Viviane | |
| dc.contributor.author | DANEL, Christine | |
| dc.contributor.author | GIRARD, Pierre Marie | |
| dc.contributor.author | TONI, Thomas D'Aquin | |
| dc.contributor.author | MINGA, Albert | |
| dc.contributor.author | BOYER, Sylvie | |
| dc.contributor.author | CARRIERI, Patrizia | |
| dc.contributor.author | ATTIA, Alain | |
| dc.date.accessioned | 2024-10-31T10:33:38Z | |
| dc.date.available | 2024-10-31T10:33:38Z | |
| dc.date.issued | 2024-05-03 | |
| dc.identifier.issn | 2045-2322 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/203078 | |
| dc.description.abstractEn | Access to Hepatis C treatment in Sub-Saharan Africa is a clinical, public health and ethical concern. The multi-country open-label trial TAC ANRS 12311 allowed assessing the feasibility, safety, efficacy of a specific care model of HCV treatment and retreatment in patients with hepatitis C in Sub Saharan Africa. Between November 2015 and March 2017, with follow-up until mid 2019, treatment-naïve patients with HCV without decompensated cirrhosis or liver cancer were recruited to receive 12 week-treatment with either sofosbuvir + ribavirin (HCV genotype 2) or sofosbuvir + ledipasvir (genotype 1 or 4) and retreatment with sofosbuvir + velpatasvir + voxilaprevir in case of virological failure. The primary outcome was sustained virological response at 12 weeks after end of treatment (SVR12). Secondary outcomes included treatment adherence, safety and SVR12 in patients who were retreated due to non-response to first-line treatment. The model of care relied on both viral load assessment and educational sessions to increase patient awareness, adherence and health literacy. The study recruited 120 participants, 36 HIV-co-infected, and 14 cirrhotic. Only one patient discontinued treatment because of return to home country. Neither death nor severe adverse event occurred. SVR12 was reached in 107 patients (89%): (90%) in genotype 1 or 2, and 88% in GT-4. All retreated patients (n = 13) reached SVR12. HCV treatment is highly acceptable, safe and effective under this model of care. Implementation research is now needed to scale up point-of-care HCV testing and SVR assessment, along with community involvement in patient education, to achieve HCV elimination in Sub-Saharan Africa. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Adult | |
| dc.subject.en | Female | |
| dc.subject.en | Humans | |
| dc.subject.en | Male | |
| dc.subject.en | Middle Aged | |
| dc.subject.en | Africa | |
| dc.subject.en | Central | |
| dc.subject.en | Africa | |
| dc.subject.en | Western | |
| dc.subject.en | Aminoisobutyric Acids | |
| dc.subject.en | Antiviral Agents | |
| dc.subject.en | Benzimidazoles | |
| dc.subject.en | Benzopyrans | |
| dc.subject.en | Carbamates | |
| dc.subject.en | Cyclopropanes | |
| dc.subject.en | Drug Therapy | |
| dc.subject.en | Combination | |
| dc.subject.en | Feasibility Studies | |
| dc.subject.en | Fluorenes | |
| dc.subject.en | Genotype | |
| dc.subject.en | Hepacivirus | |
| dc.subject.en | Hepatitis C | |
| dc.subject.en | Hepatitis C | |
| dc.subject.en | Chronic | |
| dc.subject.en | Heterocyclic Compounds | |
| dc.subject.en | 4 or More Rings | |
| dc.subject.en | Lactams | |
| dc.subject.en | Macrocyclic | |
| dc.subject.en | Leucine | |
| dc.subject.en | Proline | |
| dc.subject.en | Quinoxalines | |
| dc.subject.en | Ribavirin | |
| dc.subject.en | Sofosbuvir | |
| dc.subject.en | Sulfonamides | |
| dc.subject.en | Sustained Virologic Response | |
| dc.subject.en | Treatment Outcome | |
| dc.title.en | Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial). | |
| dc.title.alternative | Sci Rep | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1038/s41598-024-57013-1 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38702350 | en_US |
| bordeaux.journal | Scientific Reports | en_US |
| bordeaux.page | 10244 | en_US |
| bordeaux.volume | 14 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | GHIGS_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Institut de Recherche pour le Développement | en_US |
| bordeaux.identifier.funderID | Agence Nationale de Recherches sur le Sida et les Hépatites Virales | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04761770 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-10-31T10:33:42Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scientific%20Reports&rft.date=2024-05-03&rft.volume=14&rft.issue=1&rft.spage=10244&rft.epage=10244&rft.eissn=2045-2322&rft.issn=2045-2322&rft.au=LACOMBE,%20Karine&MOH,%20Raoul&CHAZALLON,%20Corine&LEMOINE,%20Maud&SYLLA,%20Babacar&rft.genre=article |
